These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36568539)

  • 21. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Duo-Ji MM; Long ZW
    Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension.
    Verlinden NJ; Benza RL; Raina A
    Pulm Circ; 2020; 10(4):2045894020945523. PubMed ID: 33354314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).
    Aldalaan AM; Saleemi SA; Weheba I; Abdelsayed A; Aleid MM; Alzubi F; Zaytoun H; Alharbi N
    Pulm Circ; 2022 Apr; 12(2):e12083. PubMed ID: 35514768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
    Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
    Wang S; Yu M; Zheng X; Dong S
    Drug Deliv; 2018 Nov; 25(1):1898-1909. PubMed ID: 30442035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.
    Gong SG; Wang L; Pudasaini B; Yuan P; Jiang R; Zhao QH; He J; Zhang R; Wu WH; Liu JM; Zhou CC
    Can Respir J; 2018; 2018():9836820. PubMed ID: 29849836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
    Moiseeva OM; Rudakova AV
    Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
    Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
    Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
    [No Abstract]   [Full Text] [Related]  

  • 36. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
    Fine N; Dias B; Shoemaker G; Mehta S
    Can J Cardiol; 2009 Mar; 25(3):e63-8. PubMed ID: 19279988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
    Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O
    PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
    Ekhlasi M; Sheikhi S; Majd ZK; Peiravian F; Yousefi N
    Value Health Reg Issues; 2023 Mar; 34():78-85. PubMed ID: 36599206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.